Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 2.64 EUR Market Closed
Market Cap: 123m EUR

EV/EBIT
Enterprise Value to EBIT

-5.3
Current
-6.1
Median
3.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-5.3
=
Enterprise Value
107.7m EUR
/
EBIT
-20.4m EUR
EBIT Growth EV/EBIT to Growth
DE
Heidelberg Pharma AG
XETRA:HPHA
Average EV/EBIT: 21.5
Negative Multiple: -5.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -209 546 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.9
28%
0.9
US
Amgen Inc
NASDAQ:AMGN
28.8
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -518.8 N/A N/A
AU
CSL Ltd
ASX:CSL
21.9
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -198.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-5.4
2-Years Forward
EV/EBIT
-4.3
3-Years Forward
EV/EBIT
-14.9